Huc-MSCs-derived exosomes attenuate neuropathic pain by inhibiting activation of the TLR2/MyD88/NF-κB signaling pathway in the spinal microglia by targeting Rsad2
Quick Facts
- Publication title: Huc-MSCs-derived exosomes attenuate neuropathic pain by inhibiting activation of the TLR2/MyD88/NF-κB signaling pathway in the spinal microglia by targeting Rsad2
- Journal: Int Immunopharmacol
- Year: 2022
- DOI: 10.1016/j.intimp.2022.109505
- PMID/PMCID: 36516531
Research overview
This study was conducted to explore the potential mechanisms underlying the analgesic effects of MSC-derived exosomes in treating neuropathic pain. This study was conducted to explore the potential mechanisms underlying the analgesic effects of MSC-derived exosomes in treating neuropathic pain.
Key findings
In vitro, huc-MSCs-derived exosomes suppressed LPS-induced microglial activation and inhibited activation of the TLR2/MyD88/NF-κB signaling pathway.
Based on the proteomic analysis, Rsad2 was identified and confirmed to be down-regulated by huc-MSCs-derived exosomes.
Importantly, knockdown of Rsad2 also inhibited microglial activation and restrained activation of the TLR2/MyD88/NF-κB signaling pathway.
In vivo, intrathecal injection of exosomes ameliorated CCI-induced mechanical allodynia, down-regulated Rsad2 expression and restrained TLR2/MyD88/NF-κB signaling activation in the spinal microglia.
Study design
Human umbilical cord MSCs (huc-MSCs)-derived exosomes were isolated and identified.
BV-2 microglia were stimulated with lipopolysaccharide (LPS) in the presence or absence of exosomes.
Differentially expressed proteins were identified by tandem mass tag (TMT)-based proteomic analysis.
Echo Biotech Role
Echo Biotech contributed EV characterization.
Related platforms: Exoomics®
Related services and capabilities: EV Basic Characterization (TEM/NTA/WB)
References
Original publication: Huc-MSCs-derived exosomes attenuate neuropathic pain by inhibiting activation of the TLR2/MyD88/NF-κB signaling pathway in the spinal microglia by targeting Rsad2 Int Immunopharmacol. 2022. DOI: 10.1016/j.intimp.2022.109505. PMID/PMCID: 36516531.